Article Text


Cardiovascular clinical pharmaceutical research
Analysis GMP-140, TAT of r-SAK and urokinase as thrombolytics in treatment of patients with acute myocardial infarction
  1. Guo-tao Wang
  1. Department of Cardiology, The Fourth Hospital of Daqing, Daqing, China


Objective To analysis the GMP-140, TAT of intravenous thrombolytic therapy using recombinant staphylokinase (r-SAK)and urokinase in acute myocardial infarction (AM I).

Methods 68 patients with AM I were randomised to receive either r-SAK or urokinase. Group A (35 cases) accepted staphylokinase was administered as intravenous bolus injections of 10 mg 30 min apart; Group B (33 cases) accepted urokinase was administered as 1.5 million units intravenous dropping within 30 min; Determination of A, B groups before thrombolytic therapy, thrombolysis, after 2 h, 24 h, 48 h in plasma platelet α-granule membrane protein (GMP-140), thrombin–antithrombin complex (TAT) levels and other related indicators.

Results A, B 2 h after treatment, the plasma GMP-140 were increased, B group of GMP-140 in plasma was significantly increased. A group 2 h after treatment, TAT concentration in plasma was not significant, B group 2 h after treatment, the plasma concentration of TAT increased significantly.

Conclusion r-SAK superior efficacy of thrombolysis with urokinase, r-SAK has a stronger selective thrombosis, procoagulant activity of weak, low incidence of bleeding complications, and promote platelet activation is low, reduce the prothrombotic state of myocardial injury can improve myocardial microperfusion.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.